684 related articles for article (PubMed ID: 24614212)
1. Inhibition of nuclear factor-κB in the lungs prevents monocrotaline-induced pulmonary hypertension in mice.
Li L; Wei C; Kim IK; Janssen-Heininger Y; Gupta S
Hypertension; 2014 Jun; 63(6):1260-9. PubMed ID: 24614212
[TBL] [Abstract][Full Text] [Related]
2. NF-κB mediated miR-130a modulation in lung microvascular cell remodeling: Implication in pulmonary hypertension.
Li L; Kim IK; Chiasson V; Chatterjee P; Gupta S
Exp Cell Res; 2017 Oct; 359(1):235-242. PubMed ID: 28755990
[TBL] [Abstract][Full Text] [Related]
3. Activation of AMPK prevents monocrotaline-induced pulmonary arterial hypertension by suppression of NF-κB-mediated autophagy activation.
Zhai C; Shi W; Feng W; Zhu Y; Wang J; Li S; Yan X; Wang Q; Zhang Q; Chai L; Li C; Liu P; Li M
Life Sci; 2018 Sep; 208():87-95. PubMed ID: 30009823
[TBL] [Abstract][Full Text] [Related]
4. Pyrrolidine dithiocarbamate restores endothelial cell membrane integrity and attenuates monocrotaline-induced pulmonary artery hypertension.
Huang J; Kaminski PM; Edwards JG; Yeh A; Wolin MS; Frishman WH; Gewitz MH; Mathew R
Am J Physiol Lung Cell Mol Physiol; 2008 Jun; 294(6):L1250-9. PubMed ID: 18390833
[TBL] [Abstract][Full Text] [Related]
5. Forsythoside B Mitigates Monocrotaline-Induced Pulmonary Arterial Hypertension via Blocking the NF-κB Signaling Pathway to Attenuate Vascular Remodeling.
Liu J; Fang G; Lan C; Qiu C; Yao L; Zhang Q; Hu J; Zhang Y; Yang Y; Zhang Y
Drug Des Devel Ther; 2024; 18():767-780. PubMed ID: 38495631
[TBL] [Abstract][Full Text] [Related]
6. A urotensin II receptor antagonist, KR36676, decreases vascular remodeling and inflammation in experimental pulmonary hypertension.
Lee JH; Park BK; Oh KS; Yi KY; Lim CJ; Seo HW; Lee BH
Int Immunopharmacol; 2016 Nov; 40():196-202. PubMed ID: 27611861
[TBL] [Abstract][Full Text] [Related]
7. Let-7a-transfected mesenchymal stem cells ameliorate monocrotaline-induced pulmonary hypertension by suppressing pulmonary artery smooth muscle cell growth through STAT3-BMPR2 signaling.
Cheng G; Wang X; Li Y; He L
Stem Cell Res Ther; 2017 Feb; 8(1):34. PubMed ID: 28187784
[TBL] [Abstract][Full Text] [Related]
8. Baicalein attenuates monocrotaline-induced pulmonary arterial hypertension by inhibiting vascular remodeling in rats.
Shi R; Wei Z; Zhu D; Fu N; Wang C; Yin S; Liang Y; Xing J; Wang X; Wang Y
Pulm Pharmacol Ther; 2018 Feb; 48():124-135. PubMed ID: 29133079
[TBL] [Abstract][Full Text] [Related]
9. Baicalein attenuates monocrotaline-induced pulmonary arterial hypertension by inhibiting endothelial-to-mesenchymal transition.
Shi R; Zhu D; Wei Z; Fu N; Wang C; Liu L; Zhang H; Liang Y; Xing J; Wang X; Wang Y
Life Sci; 2018 Aug; 207():442-450. PubMed ID: 29969608
[TBL] [Abstract][Full Text] [Related]
10. Involvement of BMPR2 in the protective effect of fluoxetine against monocrotaline-induced endothelial apoptosis in rats.
Wang Y; Zhang XH; Wang HL
Can J Physiol Pharmacol; 2011 May; 89(5):345-54. PubMed ID: 21619414
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Notch3 prevents monocrotaline-induced pulmonary arterial hypertension.
Zhang Y; Xie X; Zhu Y; Liu L; Feng W; Pan Y; Zhai C; Ke R; Li S; Song Y; Fan Y; Fan F; Wang X; Li F; Li M
Exp Lung Res; 2015; 41(8):435-43. PubMed ID: 26317171
[TBL] [Abstract][Full Text] [Related]
12. Thymosin Beta 4 protects mice from monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy.
Wei C; Kim IK; Li L; Wu L; Gupta S
PLoS One; 2014; 9(11):e110598. PubMed ID: 25412097
[TBL] [Abstract][Full Text] [Related]
13. Pathophysiological roles of nuclear factor kappaB (NF-kB) in pulmonary arterial hypertension: effects of synthetic selective NF-kB inhibitor IMD-0354.
Hosokawa S; Haraguchi G; Sasaki A; Arai H; Muto S; Itai A; Doi S; Mizutani S; Isobe M
Cardiovasc Res; 2013 Jul; 99(1):35-43. PubMed ID: 23631839
[TBL] [Abstract][Full Text] [Related]
14. [NF-κB inhibitor improves pulmonary vascular remodeling by reversing LPS-induced down-regulation of BMPRII].
Zhou MJ; Xing YJ; Yang J
Sheng Li Xue Bao; 2020 Oct; 72(5):541-550. PubMed ID: 33106824
[TBL] [Abstract][Full Text] [Related]
15. H
Feng S; Chen S; Yu W; Zhang D; Zhang C; Tang C; Du J; Jin H
Lab Invest; 2017 Mar; 97(3):268-278. PubMed ID: 27941756
[TBL] [Abstract][Full Text] [Related]
16. Farnesoid-X-receptor expression in monocrotaline-induced pulmonary arterial hypertension and right heart failure.
Ye L; Jiang Y; Zuo X
Biochem Biophys Res Commun; 2015 Nov; 467(1):164-70. PubMed ID: 26392308
[TBL] [Abstract][Full Text] [Related]
17. Resveratrol inhibits monocrotaline-induced pulmonary arterial remodeling by suppression of SphK1-mediated NF-κB activation.
Shi W; Zhai C; Feng W; Wang J; Zhu Y; Li S; Wang Q; Zhang Q; Yan X; Chai L; Liu P; Chen Y; Li M
Life Sci; 2018 Oct; 210():140-149. PubMed ID: 30179628
[TBL] [Abstract][Full Text] [Related]
18. Cardiac-specific genetic inhibition of nuclear factor-κB prevents right ventricular hypertrophy induced by monocrotaline.
Kumar S; Wei C; Thomas CM; Kim IK; Seqqat R; Kumar R; Baker KM; Jones WK; Gupta S
Am J Physiol Heart Circ Physiol; 2012 Apr; 302(8):H1655-66. PubMed ID: 22245771
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Benefits of Induced Pluripotent Stem Cells in Monocrotaline-Induced Pulmonary Arterial Hypertension.
Huang WC; Ke MW; Cheng CC; Chiou SH; Wann SR; Shu CW; Chiou KR; Tseng CJ; Pan HW; Mar GY; Liu CP
PLoS One; 2016; 11(2):e0142476. PubMed ID: 26840075
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of FGFR Signaling With PD173074 Ameliorates Monocrotaline-induced Pulmonary Arterial Hypertension and Rescues BMPR-II Expression.
Zheng Y; Ma H; Hu E; Huang Z; Cheng X; Xiong C
J Cardiovasc Pharmacol; 2015 Nov; 66(5):504-14. PubMed ID: 26535780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
